paralysis, poliomyelitis, syringomyelia, and quadriplegia; low fall and winter temperatures and low humidity and psoriasis; biotin deficiency, and abnormal metabolism of essential fatty acids have been proposed as possible mechanisms. 1 Diseases associated with Malassezia spp. are also commonly found in patients with seborrheic dermatitis, these include pityriasis versicolor and pityrosporum folliculitis. 4 Patients with seborrhoeic dermatitis may show upregulation of interferon (IFN)-g, expressed interleukin (IL)-6, expressed-IL-1a, and IL-4. Expressions of cytotoxicity activating ligands and recruitment of natural killer (NK) cells have also been noted. 2 Itraconazole is a lipophilic and keratophilic systemic antifungal agent. Seborrheic dermatitis shows marked reduction in inflammation when treated with itraconazole. It suppresses the random movement and chemotaxis of neutrophil via inhibition of interleukin-8 production in epidermal keratinocytes. 5 The anti-inflammatory activity of oral itraconazole and efficacy on Malessezia suggests that itraconazole capsule will be the first oral treatment option in future in seborrheic dermatitis. Its high lipophilicity means that it persists in the skin and appendages above the therapeutic concentration for some weeks even after the cessation of therapy (reservoir effect). This dual antifungal and anti-inflammatory effect may account for the prolong therapeutic action of low dose itraconazole. 6 Unfortunately there is no data base study with the efficacy of oral itraconazole for the treatment of seborrheic dermatitis over Bangladeshi people. Limited information is available regarding this. Here, an endeavor had been made to do such a study.
Materials and Methods:
The interventional study was carried out for a period of total two years from January 2008 to December 2009 in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka in Bangladesh. Total thirty seven patients of seborrheic dermatitis were selected considering exclusion criteria like patient with known hypersensitivity to any ingredients of the itraconazole, pregnancy/ lactation, impaired hepatic function, impaired renal function and severe systemic illness. The inclusion criteria of patient selection were include both male and female patient of any age, patient willing to give consent to take part in the study, patient expected to be available for the duration of study and able to comply with the study visit and patient received no topical treatment for 2 weeks prior to the study and no systemic antifungal intake. Purposive type nonprobability sampling technique was followed in this study. After collection of data, these were screened by checking consistency, edited and were finally analyzed by software SPSS (Statistical Package for Social Science) method.
Procedure of Treatment:
All patients with seborrheic dermatitis were treated by oral itraconazole capsule (200 mg/ day X 7 days) in first month and consecutive usage 200 mg/ day for the first 2 days of the following 11 months. Skin involvement before and after therapy was assessed by a clinical score based on the involvement of different grades of erythema, papular eruption and squamation(scale). On the initial evaluation, the patients were examined at three sites-scalp, face and chest and graded numerically at each site for erythema, papular eruption and squamation/scale: 0=normal, 1=mild, 2=moderate and 3=severe for all. Skin lesions were inspected with respect to diameter and color. The area of involvement were measured on a scale of 1 to 5. Scale 1=less than 10%, 2= 11%-30%, 3=31%-50%, 4=51%-70% and 5=more than 70% area involvement. The final assessment of the total improvement were made after 12 months. Response to therapy were rated as excellent when > 75% improvement; good when 50-75% clearing; fair when 25-50% clearing and poor when <25% clearing of skin lesion occurred.
Results:
Total thirty seven patients of seborrheic dermatitis from the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU) were subjected to this study. Table I showed that scoring of seborrhea was 6.33±1.15 before treatment and 4.33 ±3.21 after treatment, scoring of itching was 6.66 ±1.49 before treatment and 3.61 ±2.70 after treatment and scoring of greasy crust was 7.12 ±2.70 before treatment and 4.00 ±3.16 after treatment. Table II showed the distribution of patients of seborrheic dermatitis by grading of erythema, papular eruption and squamation, before and after treatment by drug. It was observed that before treatment, erythema was severe in 43.2% cases, moderate in 51.4% cases and mild type erythema was present in 5.4% cases. And after treatment, 29.7% had severe type erythema, no patient had Table III it was observed that when complaint was seborrhea, level of erythema was moderate 1 and severetreatment and after treatment, level of squamation was normal 3, mild 10, moderate 3 and severe 2 and when complaint was greasy crust, level of squamation was moderate 9 and severe 7 before treatment and after treatment, level of squamation was normal 6, mild 5 and severe 5. Figure I showed 
Conclusion:
It was evidenced that before treatment, erythema was moderate in majority of cases but after treatment, no patient had moderate type erythema, majority had mild type and more than one-fourth cases had no erythema at all. Papular eruption was moderate in majority of cases prior to the treatment but after treatment, half of the patients had mild type and one fifth had no papular eruption at all. It was further observed that before treatment, squamation was moderate in majority of cases. But following treatment, half of the patient had mild type and one-fourth had no squamation at all. Improvement was shown in three-forth cases and oneforth cases shown no improvement at all. Level of improvement was observed on the 1 st follow up visit at the end of 6 weeks. Response was fair in one-third cases and poor in halves cases. Marked improvement was noticed on the 2 nd follow up visit at the end of 12 weeks.
Response was good in three-fourth cases.
Recommendation:
The study revealed that itraconazole has remarkable efficacy profile for treatment option of seborrheic dermatitis. This was an open and uncontrolled study on a limited number of cases. Further blinded, randomized, placebo-controlled studies are needed to investigate the effectiveness of therapy. As itraconazole is still expensive, cost-effectiveness studies should be performed. If future studies include large sample size with appropriate economical support ensured and study finding would be more reliable.
